Engineered immune cells as highly sensitive cancer diagnostics. Sensitive and specific multi-cancer detection and localization using methylation signatures in cell-free DNA. Detection and localization of surgically resectable cancers with a multi-analyte blood test. Integrating genomic features for non-invasive early lung cancer detection. Benefits and harms of CT screening for lung cancer: a systematic review. Feasibility of blood testing combined with PET-CT to screen for cancer and guide intervention. Management of colorectal cancer presenting with synchronous liver metastases.
From tumour heterogeneity to advances in precision treatment of colorectal cancer. Through tailored target specificities, this modular platform has the capacity to be engineered as a pan-cancer test that may guide treatment decisions for numerous tumour types. Subsequent on-demand loading of the radiotracer 64Cu allowed pH-dependent tumour visualization, enabling enriched microenvironmental characterization when compared with the conventional metabolic tracer 18F-fluorodeoxyglucose. Specifically, we showed that acidosis-mediated tumour insertion enhanced on-target release of matrix metalloproteinase-responsive reporters in urine. We present a paradigm wherein this multimodal sensor can be employed longitudinally to assess burden of disease non-invasively, including tumour progression and response to chemotherapy. Here, we report a multimodal nanosensor engineered to target tumours through acidosis, respond to proteases in the microenvironment to release urinary reporters and (optionally) carry positron emission tomography probes to enable localization of primary and metastatic cancers in mouse models of colorectal cancer.
Therapeutic outcomes in oncology may be aided by precision diagnostics that offer early detection, localization and the opportunity to monitor response to therapy.
0 kommentar(er)
